AI Article Synopsis
- The study aimed to assess the occurrence of prostate cancer in patients with granulomatous prostatitis after receiving BCG therapy for bladder cancer.
- From 153 men treated, 6 developed symptomatic granulomatous prostatitis, indicating a 4% incidence; biopsies confirmed prostate lesions in all, with two cases of prostate cancer found.
- The findings highlight the necessity of conducting prostate biopsies for patients exhibiting elevated PSA levels and granulomatous prostatitis post-BCG treatment.
Article Abstract
Objective: The objective of this study was to evaluate the incidence of prostatic carcinoma in patients treated by intravesical BCG-therapy for superficial bladder cancer and presenting granulomatous prostatitis. The authors discuss the problems of interpretation of total PSA and the potential indications for prostatic biopsies in this population.
Material And Methods: A retrospective study was performed on the cases of symptomatic granulomatous prostatitis observed among patients treated with intravesical BCG instillations between January 1997 and December 2006. A total of 153 men were treated for high-risk or intermediate-risk superficial bladder cancer according to the usual recommendations. The attenuated Connaught strain of BCG was used at a dose of 81 mg. Induction treatment consisted of six weekly instillations and was followed by maintenance treatment for a period of three years.
Results: Six patients developed symptomatic granulomatous prostatitis (4% of cases). On average, this complication occurred after about the 10th intravesical instillation (6-13) of maintenance treatment. The mean total PSA at three months was 8 ng/ml (range: 5-11.6). Ultrasound-guided biopsies were indicated in view of the persistently elevated PSA level and confirmed the tuberculoid granulomatous lesion of the prostate in each case and revealed prostatic adenocarcinoma in two patients.
Conclusion: Prostatic carcinoma must be systematically excluded by ultrasound-guided biopsies in all patients with clinical granulomatous prostatitis and persistently elevated PSA three months after intravesical BCG instillations.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.purol.2007.12.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design of Nanocrystalline Suspension of Dutasteride for Intramuscular Prolonged Delivery.
Nanomaterials (Basel)
November 2024
College of Pharmacy, Dankook University, 119 Dandae-ro, Dongnam-gu, Cheonan 31116, Chungnam, Republic of Korea.
The aim of the study is to formulate an injectable nanocrystalline suspension (NS) of dutasteride (DTS), a hydrophobic 5α-reductase inhibitor used to treat benign prostatic hyperplasia and scalp hair loss, for parenteral long-acting delivery. A DTS-loaded NS (DTS-NS, 40 mg/mL DTS) was prepared using a lab-scale bead-milling technique. The optimized DTS-NS prepared using Tween 80 (0.
View Article and Find Full Text PDFBackground: Detecting carcinoma prostate (CaP) after intravesical Bacillus Calmette Guerin (BCG) immunotherapy for non-muscle invasive bladder cancer (NMIBC) poses diagnostic challenges. Granulomatous prostatitis (GP) has an incidence of 0.8%-3.
View Article and Find Full Text PDFGranulomatous prostatitis following Bacillus Calmette-Guérin therapy.
J Clin Imaging Sci
October 2024
Department of Radiology, Anatomy and Laboratory Medicine, West Virginia University, Morgantown, United States.
Article Synopsis
- - Granulomatous prostatitis (GP) is a rare type of chronic prostatitis, occurring in 0.65-1.5% of cases, and can show similar imaging characteristics to prostate cancer.
- - Key MRI features suggesting GP include low T2 signal, high diffusion-weighted imaging signals, and lesion enhancements post-contrast, particularly in cases with necrosis or abscesses.
- - A case study discusses a 70-year-old man with GP following treatment with intravesical bacillus Calmette-Guérin, highlighting the importance of biopsy for accurate diagnosis due to the imaging similarities with prostate adenocarcinoma.
Introduction: Xanthogranulomatous prostatitis is a very rare benign inflammatory lesion of the prostate that may be similar to prostatic carcinoma in clinical presentation and radiological characteristics.
Case Presentation: A 77-year-old man was admitted to our hospital because of high prostate-specific antigen level. Magnetic resonance imaging showed a 6.
Article Synopsis
- Granulomatous prostatitis (GP) is a rare, non-cancerous inflammation of the prostate that can mimic prostate cancer (PCa) during evaluations.
- The study analyzed 12 patients who developed GP after receiving BCG therapy for bladder cancer, focusing on their symptoms, MRI results, and tissue examination.
- Histopathological analysis is crucial to accurately diagnose GP, as it differentiates it from PCa by identifying granulomas, emphasizing the need for a combined clinical and imaging approach to prevent unnecessary treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!